Search research articles
Contact Us
Filters
Showing results (21-30 of 130) with videos related to
Page
of 13
Sort By:
Frontiers in Immunology
|
September 3, 2019
Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid
Christian D Sadik, Ewan A Langan, Victoria Grätz, et al.
The Lancet. Oncology
|
January 8, 2020
Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
Ewan A Langan, Victoria Graetz, Judith Allerheiligen, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
November 16, 2005
Treatment of scleromyxoedema with hydroxychloroquine
Patrick Terheyden, Jürgen C Becker, Christa Lurz, et al.
The Journal of Investigative Dermatology
|
October 9, 2009
Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene
Patrick Terheyden, Roland Houben, Parisa Pajouh, et al.
Dermatologic Therapy
|
April 12, 2019
Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma
Ewan A Langan, Christiane Kümpers, Victoria Graetz, et al.
Journal of Cancer Research and Clinical Oncology
|
June 23, 2007
Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
Patrick Terheyden, Maja Ann Hofmann, M Weininger, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|
November 14, 2019
[Supportive therapy and management of side effects in dermato-oncology]
Laura von Dücker, Svea Hüning, Katharina Kähler, et al.
International Journal of Molecular Sciences
|
September 23, 2022
Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center
Jonas K Kurzhals, Gina Klee, Victoria Hagelstein, et al.
Melanoma Research
|
July 20, 2022
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
Gina Klee, Victoria Hagelstein, J K Kurzhals, et al.
Melanoma Research
|
July 20, 2021
Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
Gina Klee, Jonas Kurzhals, Victoria Hagelstein, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 130) with videos related to
Sort By:
Page
of 13
Frontiers in Immunology
|
September 3, 2019
Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid
Christian D Sadik, Ewan A Langan, Victoria Grätz, et al.
The Lancet. Oncology
|
January 8, 2020
Immune checkpoint inhibitors and tuberculosis: an old disease in a new context
Ewan A Langan, Victoria Graetz, Judith Allerheiligen, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
November 16, 2005
Treatment of scleromyxoedema with hydroxychloroquine
Patrick Terheyden, Jürgen C Becker, Christa Lurz, et al.
The Journal of Investigative Dermatology
|
October 9, 2009
Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene
Patrick Terheyden, Roland Houben, Parisa Pajouh, et al.
Dermatologic Therapy
|
April 12, 2019
Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma
Ewan A Langan, Christiane Kümpers, Victoria Graetz, et al.
Journal of Cancer Research and Clinical Oncology
|
June 23, 2007
Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
Patrick Terheyden, Maja Ann Hofmann, M Weininger, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|
November 14, 2019
[Supportive therapy and management of side effects in dermato-oncology]
Laura von Dücker, Svea Hüning, Katharina Kähler, et al.
International Journal of Molecular Sciences
|
September 23, 2022
Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center
Jonas K Kurzhals, Gina Klee, Victoria Hagelstein, et al.
Melanoma Research
|
July 20, 2022
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
Gina Klee, Victoria Hagelstein, J K Kurzhals, et al.
Melanoma Research
|
July 20, 2021
Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
Gina Klee, Jonas Kurzhals, Victoria Hagelstein, et al.
Page
of 13